Certain Stage 3 Colon Cancer Patients May Benefit from Irinotecan-Based Therapy
the Cancer Therapy Advisor take:
According to a new study published in the journal Gastroenterology, a certain subset of stage 3 colon cancer patients had increased survival rates when treated with irinotecan, leucovorin, and fluorouracil (5-FU) compared with leucovorin and 5-FU alone.
In the study, researchers from the Fred Hutchinson Cancer Research Center in Seattle, Washington, analyzed data from patients with stage 3 colon adenocarcinoma randomly assigned to groups given irinotecan-based therapy or leucovorin and 5-FU from 1999 to 2001. Researchers identified 145 patients whose colon cancer had the CpG island methylator phenotype (CIMP), defined by an increased frequency of aberrantly methylated genes.
Researchers found that patients with CIMP-positive colon cancer had a shorter duration of overall survival compared with patients with CIMP-negative tumors. Furthermore, CIMP-positive patients treated with irinotecan-based therapy trended toward an increased overall survival versus those treated with leucovorin and 5-FU (P=0.07); however, this trend was not observed in patients with CIMP-negative colon cancer.
In addition, researchers observed the most benefit of irinotecan-based therapy in patients with CIMP-positive, mismatch repair (MMR)-intact tumors (P=0.01). They also found KRAS or BRAF mutation status did not affect the effectiveness of treatment.
Colon cancer patients had improved survival rates when treated with irinotecan-based therapy.
A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.
When added to the standard chemotherapy treatment—fluorouracil and leucovorin—adjuvant irinotecan therapy improved overall survival rates for patients with the CpG island methylator phenotype (CIMP).
CIMP is seen in about 10 to 20 percent of colorectal cancers. Patients with CIMP-negative tumors, however, exhibited significant harm from the addition of irinotecan—overall survival was 68 percent compared with 78 percent for those receiving the standard treatment alone.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer